A Pharmacogenetic Study of <i>CYP2C19</i> in Acute Coronary Syndrome Patients of Colombian Origin Reveals New Polymorphisms Potentially Related to Clopidogrel Therapy
Clopidogrel, an oral platelet P2Y<sub>12</sub> receptor blocker, is used in the treatment of acute coronary syndrome. Interindividual variability in treatment response and the occurrence of adverse effects has been attributed to genetic variants in <i>CYP2C19</i>. The analysi...
Main Authors: | Mariana Angulo-Aguado, Karen Panche, Caroll Andrea Tamayo-Agudelo, Daniel-Armando Ruiz-Torres, Santiago Sambracos-Parrado, Maria Jose Niño-Orrego, Nathaly Páez, Laura B Piñeros-Hernandez, Luisa-Fernanda Castillo-León, Juan Mauricio Pardo-Oviedo, Katherine Parra Abaunza, Paul Laissue, Nora Contreras, Carlos Alberto Calderón-Ospina, Dora Janeth Fonseca-Mendoza |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Journal of Personalized Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4426/11/5/400 |
Similar Items
-
CLOPIDOGREL PHARMACOGENETICS
by: A. N. Meshkov
Published: (2016-01-01) -
Risk factors for adverse drug reactions associated with clopidogrel therapy
by: Mugosa Snezana, et al.
Published: (2022-04-01) -
An Integrated Multidisciplinary Circuit Led by Hospital and Community Pharmacists to Implement Clopidogrel Pharmacogenetics in Clinical Practice
by: Joan Francesc Mir, et al.
Published: (2023-04-01) -
CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic
by: Seyed abbas Mirabbasi, et al.
Published: (2017-07-01) -
THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015-09-01)